Commentary

JCP
Evolving Care and Research Priorities in ADHD
Commentary

December 23, 2024

Surman and Wilens discuss two recent JCP articles highlighting that how ADHD manifests can be heavily influenced by context, as well as individual vulnerabilities and strengths.
,
JCP
The Opioid Industry's Legacy: A Generation of Prescribed Suffering
Commentary

December 18, 2024

The authors discuss the influential and far-reaching effects of messaging from the opioid industry on the opioid use epidemic.
,
JCP
SUD Programs for Transgender and Gender Diverse Patients
Commentary

November 11, 2024

The authors discuss responsiveness of transgender and gender diverse patients to SUD treatment at different care levels (eg, outpatient, residential, inpatient), as well as how to reduce stressors and...
,
JCP
Clinical Implications of Adult ADHD: What New Data Tell Us
Commentary

October 10, 2024

The authors discuss striking new findings from the Morbidity and Mortality Weekly Report on the burden of adult ADHD, demonstrating the need for the upcoming APSARD Adult ADHD Guidelines.
,
JCP
Reproductive Pharmacovigilance and Best Practices
Commentary

August 26, 2024

Dr Freeman discusses a recent study by Pacilio et al that characterized real world practices around ketamine treatment and pregnancy testing, consent processes, and contraception use. She emphasizes the...
JCP
Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
Commentary

August 21, 2024

Dr Rosenbaum comments on the challenge of evaluating trials of treatments whose effects are unmistakable, and how this dilemma may be addressed.
JCP
Can Our Collective Experiences As Clinicians Improve Mental Health Care?
Commentary

July 17, 2024

Drs Rush and Tramontin discuss how simple outcomes, often patient reported, could facilitate evidence-based decision making by clinicians, administrators, and payors and provide the foundation for a learning health...
,
JCP
Extreme Dysphoria of Pregnancy: A Distinct Syndrome Warranting Attention?
Commentary

June 10, 2024

Dr Freeman discusses the understudied phenomenon of pregnancy-related extreme dysphoria or depression, distinct from typical major depressive episodes. Three illustrative case vignettes are presented.
JCP
Sleep Alterations as Proximal Markers for Suicide Risk
Commentary

June 3, 2024

Dr Geoffroy discusses recent research exploring the links between suicide and sleep disturbances.
JCP
Co-occurrence of Depression and Obesity: Implications for Practice and the Discovery of Targeted and Mechanistically Informed Therapeutics
Commentary

June 3, 2024

Dr McIntyre discusses the implications of recent research by Baek et al.
JCP
The Long Road Toward Equitable MDMA Treatment in the United States
Commentary

May 29, 2024

Kozak and Aaronson discuss challenges in implementation of MDMA-assisted therapy, including insurance and Medicare coverage as well as cultural barriers.
,
JCP
Enhancing Postpartum Psychosis Care
Commentary

May 29, 2024

The authors discuss the need for qualitative research to fill gaps in the current understanding of postpartum psychosis, as well as the barriers that make conducting this research a...
, , , et al
JCP
How to Value a Life Without Limits: Quantifying Suffering With Quality-Adjusted Life Years in Social Anxiety Disorder
Commentary

May 27, 2024

The authors discuss a recent intriguing study published in JCP by Patel et al.
,
JCP
Psychosis, Inflammatory Biomarkers, and Subtypes of Childhood Trauma
Commentary

May 22, 2024

Dr Nasrallah discusses a recent study by Cuñat et al of the relationship between childhood trauma and inflammation, and why this work is unique and important.
JCP
Valproate and Weight Gain: A New Look at an Old Problem
Commentary

March 27, 2024

Dr Goldberg comments on a recent cohort study demonstrating a dose relationship with weight gain liability for valproate.
JCP
What Does a Systematic Review of Cannabis and PTSD Tell Us? That We Need to Learn More
Commentary

February 14, 2024

Dr Ostacher discusses a review by Rodas et al and points to a need for clear answers on how best to advise patients with PTSD and other psychiatric illness...
JCP
Enriching the Assessment of Suicidal Ideation
Commentary

January 17, 2024

The processes involved in the generation of suicidal ideation (SI) can be distinguished from those involved in the acts themselves. This commentary notes that the rise of digital health...
,
JCP
The Psychological Burden of ALS, the Enduring Strength of People Living With ALS, and the Tools We Can Use to Help
Commentary

December 13, 2023

Commenting on a recent article by Lester et al, the authors discuss the psychological impacts of diagnosis, genetic testing, and disease progression on patients with amyotrophic lateral sclerosis (ALS).
,
JCP
Long-Term Benzodiazepine Treatment: Toward Evidence-Based Practice Guidelines
Commentary

October 25, 2023

The evidence about long-term benzodiazepine use presents a confounding paradox. This commentary proposes a set of prescribing guidelines for clinicians.
, , , et al
JCP
COVID-19 Delirium and Motoric Subtypes: Improving Outcomes
Commentary

August 21, 2023

Randall T. Espinoza, MD, and Aaron Kaufman, MD, discuss a study by Trevisan et al and reflect on lessons learned during the pandemic about detecting and managing delirium.
,
JCP
The Potential Power of Virtual Group CBT
Commentary

July 24, 2023

Rachel Vanderkruik, PhD, MSc, discusses Huh and colleagues’ study of online nurse-delivered group CBT for postpartum depression, highlighting 4 key aspects that make the intervention particularly exciting.
JCP
Clinical Follow-Up and Widening LAI Intervals
Commentary

May 31, 2023

Although the administration intervals of long-acting injectable antipsychotics are a starting point for scheduling follow-ups, frequency of prescriber contact should be based on individual risk factors and real-world constraints.
, ,
JCP
rTMS for Treatment-Resistant Depression: Mismatch of Evidence and Insurance Coverage Policies
Commentary

April 26, 2023

The authors argue that insurance companies’ prior authorization process overly restricts access to rTMS, which has proven effectiveness for TRD.
, , , et al
JCP
The Emerging Treatment Landscape in Schizophrenia
Commentary

January 18, 2023

This article provides an overview of emerging therapies poised to transform the treatment paradigm for patients with living with schizophrenia.
,

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe